Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?

Area of Science:

• Oncology
• Immunotherapy
• Gastrointestinal Oncology

Background:

• Advanced esophageal cancer historically has a poor prognosis with limited treatment options.
• Immunotherapy, specifically checkpoint inhibitors, has emerged as a promising treatment modality.
• Nivolumab and pembrolizumab have shown significant efficacy in both advanced and resectable esophageal cancer.

Purpose of the Study:

• To review recent clinical data on immunotherapeutic agents for esophageal cancer.
• To critically evaluate the potential limitations of implementing these therapies in unselected patient populations.

Main Methods:

• Review of recent clinical trial data on immunotherapy for esophageal cancer.
• Critical analysis of efficacy, toxicity, and patient selection criteria.

Main Results:

• Checkpoint inhibitors (nivolumab, pembrolizumab) demonstrate revolutionary response rates.
• Clinical trials indicate high efficacy, tolerable toxicity, improved survival, and sustained quality of life.
• Concerns regarding optimal patient selection and therapy implementation persist.

Conclusions:

• Immunotherapy represents a paradigm shift in esophageal cancer treatment.
• Further research is needed to define patient populations most likely to benefit and address implementation challenges.